Evidence map›Paper›PMID 41585228›Full record

ReviewFrontiers in medicine2025

Application of surface-enhanced Raman spectroscopy in the diagnosis and treatment of breast cancer.

Xin-Xin Luo, Meng-Ye He, Meng-Li Luo, Yun-Lu Jia, Peng Shen

Abstract readReview
In one paragraph

Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xin-Xin Luo *Department of Internal Medicine, Yuyao Maternity and Child Health Care Hospital, Ningbo, Zhejiang, China.
Meng-Ye He *Department of Medical Oncology, The First Affiliated Hospital, Medical College of Zhejiang University, Hangzhou, Zhejiang, China.
Meng-Li LuoDepartment of Internal Medicine, Yuyao Maternity and Child Health Care Hospital, Ningbo, Zhejiang, China.
Yun-Lu JiaDepartment of Medical Oncology, The First Affiliated Hospital, Medical College of Zhejiang University, Hangzhou, Zhejiang, China.
Peng ShenDepartment of Medical Oncology, The First Affiliated Hospital, Medical College of Zhejiang University, Hangzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current tumour diagnosis relies on patient symptoms, physical signs, and imaging findings supplemented by the gold standard, pathological examination. Posttreatment efficacy evaluation also primarily depends on imaging aided by blood tests, such as tumour marker tests, which often require invasive procedures. In recent years, scientists have explored more sensitive and noninvasive tumour diagnostic technologies. Owing to its single-molecule level sensitivity, fingerprint-like specificity, synchronous multicomponent detection capability, noninvasiveness, and potential for rapid analysis, surface-enhanced Raman scattering (SERS) technology has gradually gained attention in the medical field, particularly for tumour diagnosis and treatment. This article systematically reviews SERS detection for breast cancer diagnosis and therapy.

Indexed as

breast cancerearly detectionliquid biopsysurface-enhanced Raman spectroscopytumour diagnosis

Identifiers

PMID41585228
PMCPMC12827618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.